BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11442187)

  • 1. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
    Lee DA; Gornbein JA
    J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST; Samuelson TW
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.
    Lee DA
    Clin Ther; 2000 Jan; 22(1):53-65. PubMed ID: 10688390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
    Mundorf T; Noecker RJ; Earl M
    Adv Ther; 2007; 24(2):302-9. PubMed ID: 17565920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
    Lee DA; Gornbein J; Abrams C
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST;
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
    Camras CB; Sheu WP;
    J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
    Javitt J; Goldberg I
    J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
    Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
    J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.